Paper Details

  1. Home
  2. Paper Details

Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.

Author: Al-BatranSalah-Eddin, BrulinTanita, GoekkurtEray, GoetzeThorsten Oliver, HabibzadaTimorshah, HerhausPeter, IhrigKristina, LooseMaria, LorenzenSylvie, PauligkClaudia, SookthaiDisorn, SteinAlexander

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This pilot trial explored the safety and efficacy of combining ramucirumab with TAS-102 in patients with advanced esophagogastric adenocarcinoma who had progressed on prior therapies. The combination showed a favorable safety profile with a lower incidence of adverse events compared to historical data. It also demonstrated efficacy in terms of tumor response and overall/progression-free survival, warranting further evaluation in a randomized trial.
Paper Details　
Original Abstract of the Article :
Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS-102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter, non-randomized, open-label, investigator-initiated pilot tria...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/ijc.34652

データ提供：米国国立医学図書館（NLM）

Ramucirumab: A New Hope for Advanced Esophagogastric Adenocarcinoma

The field of oncology is constantly seeking new and innovative therapies for advanced cancers. This multicenter, non-randomized pilot trial investigates the combination of ramucirumab and TAS-102 (trifluridine/tipiracil) in patients with advanced or metastatic esophagogastric adenocarcinoma (EGA) who have previously failed ramucirumab-based therapy. The researchers found that this combination demonstrated a favorable safety profile with a numerically lower incidence of side effects compared to historical data. The combination also showed promising efficacy, with a disease control rate of 45% and a median overall survival of 9.1 months. This study suggests that this combination warrants further evaluation in a randomized trial, potentially offering a new treatment option for patients with EGA.

A Promising Combination for Advanced Esophagogastric Adenocarcinoma

This pilot trial demonstrates the potential of combining ramucirumab and TAS-102 as a promising treatment option for patients with EGA who have failed previous ramucirumab-based therapy. The researchers observed a favorable safety profile and encouraging efficacy, suggesting that this combination warrants further investigation in a larger, randomized trial. This research offers hope for patients with EGA, potentially providing a new treatment option that could improve outcomes and extend survival.

Navigating the Treatment Landscape for Advanced EGA

This study highlights the need for continued research and development in the field of oncology to provide more effective treatment options for patients with EGA. The researchers' findings suggest that the combination of ramucirumab and TAS-102 warrants further investigation, potentially offering a new therapeutic approach that could improve survival and quality of life for individuals with this challenging disease. This research encourages a more personalized and tailored approach to cancer treatment, exploring innovative combinations of therapies to optimize outcomes for patients with advanced cancer.

Dr.Camel's Conclusion

Like a skilled caravan leader guiding a group through a challenging desert landscape, researchers are exploring new treatment combinations to navigate the complexities of advanced EGA. This pilot trial offers a promising glimpse into the potential of combining ramucirumab and TAS-102, underscoring the importance of continued research and development to identify more effective therapies for patients with this challenging disease.

Date :
  1. Date Completed 2023-09-19
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

37455496

DOI: Digital Object Identifier

10.1002/ijc.34652

Related Literature

Article Analysis
・Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.